Controlled release systems of growth factors using heparinized polymeric carriers

Tissue Engineering and Regenerative Medicine

Volumn 5, Issue 2, 2008, Pages 156-164

  Joung, Yoon Ki ^a   Park, Ki Dong ^a  

^a Ajou University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77950392458     PISSN: 17382696     EISSN: 22125469     Source Type: Journal    
DOI: None     Document Type: Article

References (97)

1. IA McKay, In Growth Factors: A Practical Approach, IRL Press: Oxford, (1993).
2. T Boontheekul, DJ Mooney, Protein-based signaling systems in tissue engineering, Curr. Opin. Biotech., 14, 559 (2003).
3. UT Iwaniec, KA Magee, NG Mitova-Caneva, et al., Bone anabolic effects of subcutaneous treatment with basic fibroblast growth factor alone and in combination with estrogen in osteogenic ovariectomized rats, Bone, 33, 380 (2003).
4. Y Tao, IB Black, E Dicicco-Bloom, Neurogenesis in neuronatal rat brain is regulated by peripheral injection of basic fibroblast growth factor(bFGF), J. Comp. Neurol., 376, 653 (1996).
5. G Schifitto, C Yiannoutsos, DM Simpson, et al., Long-term treatment with recombinant nerve growth factor for HIVassociated sensory neuropathy, Neurology, 57, 1313 (2001).
6. Y Ueda, T Yamagishi, H Ikeya, et al., A novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo, Anticancer Res., 24, 3009 (2004).
7. LS Rosen, Clinical experience with angiogenesis signaling inhibitors: Focus on vascular endothelial growth factor(VEGF) blockers, Cancer Control, 9, 36 (2002).
8. AM Byrne, DJ Bouchier-Hayes, JH Harmey, Angiogenic and cell survival functions of vascular endothelial growth factor(VEGF), J. Cell. Mol. Med. 9, 777 (2005).
9. I Capila, RJ Linhardt, Heparin-protein interactions, Angew. Chem. Int. Ed. 41, 390 (2002).
10. C Yao, P Prevel, S Koch, et al., Modification of collagen matrices for enhancing angiogenesis, Cells Tissues Organs, 178, 189 (2004).
11. GCM Steffens, C Yao, P Prevel, et al., Modulation of angiogenic potential of collagen matrices by covalent incorporation of heparin and loading with VEGF, Tissue Eng., 10, 1502 (2004).
12. PK Shireman, HP Greisler, Mitogenicity and release of vascular endothelial growth factor with and without heparin from fibrin glue, J. Vasc. Surg., 31, 936 (2000).
13. DSW Benoit, KS Anseth, Heparin functionalized PEG hydrogels that modulate protein adsorption for hMSC adhesion and differentiation, Acta Biomater., 1, 461 (2005).
14. YI Yang, HI Kim, JY Seo, et al., Adult stem cells as cell therapeutics for angiogenesis, Tissue Eng. Regen, Med., 4(4), 484 (2007).
15. OJ Jeon, SH Ryu, JH Chung, et al., Control of basic fibroblast growth factor release from fibrin gel with heparin and concentrations of fibrinogen and thrombin, J. Control. Release, 105, 249 (2005).
16. M Fujita, M Ishihara, M Simizu, et al., Vascularization in vivo caused by the controlled release of fibroblast growth factor-2 from an injectable chitosan/non-anticoagulant heparin hydrogel, Biomaterials, 25, 699 (2004).
17. LS Liu, CK Ng, AY Thompson, et al., Hyaluronate-heparin conjugate gels for the delivery of basic fibroblast growth factor(FGF-2), J. Biomed. Mater. Res., 62, 128 (2002).
18. SE Sakiyama-Elbert, JA Hubbell, Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix, J. Control. Release, 69, 149 (2000).
19. AC Lee, VM Yu, JB Lowe, et al., Controlled release of nerve growth factor enhances nerve regeneration, Exp. Neurol., 184, 295 (2003).
20. JA Schroeder-Tefft, H Bentz, TD Estridge, Collagen and heparin matrices for growth factor delivery, J. Control. Release, 49, 291 (1997).
21. SP Baldwin SP, WM Saltzman WM, Materials for protein delivery in tissue engineering, Adv. Drug. Deliver. Rev., 33, 71 (1998).
22. G Khang, SH Kim, MS Kim, et al., Role of cytokines for the treatment of intervertebral disc using regenerative medicine, Tissue Eng. Regen, Med., 4(4), 490 (2007).
23. M Joyce, A Roberts, M Sporn, M Bolander, Transforming growth factor and the initiation of chondrogenesis and osteogenesis in the rat femur, J. Cell Biol. 110, 2195 (1990).
24. L Lu, GN Stamatas, AG Mikos, Controlled release of transforming growth factor1 from biodegradable polymer microparticles, J. Biomed. Mater. Res., 50, 440 (2000).
25. SJ Peter, L Lu, DJ Kim, et al., Effects of transforming growth factor 1 released from biodegradable polymer microparticles on marrow stromal osteoblasts cultured on poly (propylene fumarate) substrates, J. Biomed. Mater. Res., 50, 452 (2000).
26. RL Cleek, AA Rege, LA Denner, et al., Inhibition of smooth muscle cell growth in vitro by an antisense oligodeoxynucleotide released from poly(DL-lactic-co-glycolic acid) microparticles, J. Biomed. Mater. Res., 35, 525 (1997).
27. L Dailey, D Ambrosetti, A Mansukhani, C Basilico, Mechanisms underlying differential responses to FGF signaling, Cytokine Growth F. R., 16, 233 (2005).
28. A Perets, Y Baruch, F Weisbuch, et al., Enhancing the vascularization of three-dimensional porous alginate scaffolds by incorporating controlled release basic fibroblast growth factor microspheres, J. Biomed. Mater. Res. A, 65A, 489 (2003).
29. T Suetomi, SI Hisasue, Y Sato, et al., Effect of basic fibroblast growth factor incorporating cleatin microspheres on erectile function in the diabetic rat, J. Urol., 173, 1423 (2005).
30. RS Rogers, TM Graziottin, CS Lin, et al., Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats, Int. J. Impot. Res., 15, 26 (2003).
31. Q Dai, AD Silverstein, MG Davies, et al., Systemic Basic Fibroblast Growth Factor Induces Favorable Histological Changes in the Corpus Cavernosum of Hypercholesterolemic Rabbits, J. Urol., 170, 664 (2003).
32. G Khang, SH Kim, MS Kim, et al., Recent and future directions of stem cells for the application of regenerative medicine, Tissue Eng. Regen, Med., 4(4), 441 (2007).
33. N Ferrara, Role of vascular endothelial growth factor in regulation of physiological angiogenesis, Am. J. Physiol. Cell Physiol., 280, c1358 (2001).
34. S Banai, MT Jaklitsch, M Shou, et al., Angiogenic-induced. enhancement of collateral blood flow to ischemic myocardium. by vascular endothelial growth factor in dogs, Circulation, 89, 2183 (1994).
35. JD Pearlman, MG Hibberd, ML Chuang, et al., Magnetic resonance mapping demon-strate benefits of VEGF-induced myocardial: angiogenesis, Nat. Med., 1, 1085 (1995).
36. K Harada, M Friedman, JJ Lopez, et al., Vascular endothelial growth factor administration in chronic myocardial ischemia, Am. J. Physiol., 270, h1791 (1996).
37. RJ Lee, ML Springer, WE Blanco-Bose, et al., VEGF gene delivery to myocardium: Deleterious effects of unregulated expression, Circulation, 102, 898 (2000).
38. TW King, CW Patrick Jr., Development and in vitro characterization of vascular endothelial growth factor (VEGF)-loaded poly(D,L-lactic-co-glycolic acid)/poly(ethylene glycol) microspheres using a solid encapsulation/single emulsion/solvent extraction technique, J. Biomed. Mater. Res., 51, 383 (2000).
39. L Jeffrey, Cleland, ET Duenasa, A Parka, et al., Development of poly(D,L-lactide-coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis, J. Control. Release, 72, 13 (2001).
40. AZ Faranesh, Nastley, CPD Cruz, et al., Theoretical and experimental investigation of the VASO contrast mechanism, Magn. Reson. Med., 51, 1265 (2004).
41. LW Norton, E Tegnella, SS Toporekb, WM Reichert, in vitro characterization of vascular endothelil growth factor and dexamethasone releasing hydrogels for implantable probe coatings, Biomaterials, 26, 3285 (2005).
42. G Conn, DD Soderman, MT Schaeffer, et al., Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line, Proc. Natl. Acad. Sci. USA, 87, 1323 (1990).
43. NN Nissen, PJ Polverini, AE Koch, et al., Vascular. endothelial growth factor mediates angiogenic activity during the proliferative. phase of wound healing, Am. J. Pathol., 152, 1445 (1998).
44. E Shibayama, H Koizumi, Cellular localization of the trk neurotrophin receptor family in human non-neuronal tissues, Am. J. Pathol., 148, 1807 (1996).
45. JS Park, JH Lee, HS Shin, et al., Microemulsions as carriers for drugs and nutraceuticals, Tissue Eng. Regen, Med., 4(4), 502 (2007).
46. S Mittal, A Cohen, D Maysinger, in vitro effects of brain derived neurotrophic factor released from microspheres, Neuroreport, 5, 2577 (1994).
47. CE Krewson, R Dause, M Mak, WM Saltzman, Stabilization of nerve growth factor in controlled release polymers and in tissue, J. Biomater. Sci. Polymer Ed., 8, 103 (1996).
48. JM Péan, P Menei, O Morel, et al., Intraseptal implantation of NGF-releasing microspheres promotes the survival of axotomized cholinergic neurons, Biomaterials, 21, 2097 (2000).
49. CN Montero, F Hefti, Rescue of lesioned septal cholinergic neurons by nerve growth factor: specificity and requirement for chronic treatment, J. Neurosci., 8, 2986 (1998).
50. JM Péan, MC Venier-Julienne, R Filmon, et al., Optimization of HSA and. NGF encapsulation yields in PLGA microparticles. Int. J. Pharm., 166, 105 (1998).
51. JM Péan, MC Venier-Julienne, F Boury, et al., NGF release from poly(D,L-lactide-co-glycolide) microspheres. Effect of some formulation parameters on encapsulated NGF stability, J. Control. Release, 56, 175 (1998).
52. VM Knepp, DM Lidgate, R Maskiewicz, I Gu, Pharmaceutical formulations of nerve growth factor. USP6277828 (2001).
53. GEP Box, WG Hunter, JS Hunter, Statistics for Experimenters. Wiley, (1978).
54. JH Lee, HH Ahn, YN Shin, et al., Gene delivery using a cationic polymer carrier, Tissue Eng. Regen, Med., 4(3), 341 (2007).
55. X Cao, MS Shoichet, Delivering neuroactive molecules from biodegradable microspheres for application in central nervous system disorders, Biomaterials, 20, 329 (1999).
56. A Piotrowicza, MS Shoichet, Nerve guidance channels as drug delivery vehicles, Biomaterials, 27, 2018 (2006).
57. X Xu, H Yu, S Gao, HQ Mao, et al., Polyphosphoester microspheres for sustained release of biologically active nerve growth factor, Biomaterials, 23, 3765 (2002).
58. X Xu, WC Yee, PYK Hwang, et al., Peripheral nerve regeneration with sustained release of poly(phosphoester) microencapsulated nerve growth factor within nerve guide conduits, Biomaterials, 24, 2405 (2003).
59. M Richards, BI Dahiyat, DM Arm, et al., Evaluation of polyphosphates and polyphosphonates as degradable biomaterials, J. Biomed. Mater. Res., 25, 1151 (1991).
60. BI Dahiyat, E Hostin, EM Posadas, KW Leong, Synthesis and characterization of putrescine-based poly(phosphoesterurethanes). J. Biomater. Sci. Polym. Ed., 4, 529 (1993).
61. HQ Mao, I Shipanova-Kadiyaia, Z Zhao, et al., Encyclopedia of controlled drug delivery. NewYork: Wiley, (1999).
62. S Wang, AC Wan, X Xu, et al., A new nerve guide conduit material composed of a biodegradable poly(phosphoester). Biomaterials, 22, 1157 (2001).
63. O Jeon, SW Kang, HW Lim, et al., Long-term and zeroorder release of basic fibroblast growth factor from heparinconjugated poly(lactide-co-glycolide) nanospheres and fibrin gel, Biomaterials, 27, 1598 (2006).
64. SK Kim, EH Lee, B Vaishali, et al., Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates, J. Control. Release, 105, 32 (2005).
65. HT Moon, YK Lee, JK Han, Y Byun, A novel formulation for controlled release of heparin-DOCA conjugate dispersed as nanoparticles in polyurethane film, Biomaterials, 22, 281 (2001).
66. DY Lee, SK Kim, YS Kim, et al., Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate, J. Control. Release, 118, 310 (2007).
67. JS Lee, DH Go, JW Bae, et al., Synthesis and characterization of heparin conjugated Tetronic-PCL copolymer for protein drug delivery, Curr. Appl. Phys., 7S1, 49 (2007).
68. JS Lee, DH Go, JW Bae, et al., Heparin conjugated polymeric micelle for long-term delivery of basic fibroblast growth factor, J. Control. Release, 117, 204 (2007).
69. JS Lee, JW Bae, YK Joung, et al., Controlled dual release of basic fibroblast growth factor and indomethacin from heparin-conjugated polymeric micelle, Int. J. Pharm., 346, 57 (2008).
70. SH Choi, JH Lee, SM Choi, et al., Thermally reversible Pluronic/heparin nanocapsules exhibiting 1000-fold volume transition, Langmuir, 22, 1758 (2006).
71. GM Qiu, YY Xu, BK Zhu, et al., Novel, fluorescent, magnetic, polysaccharide-based microsphere for orientation, tracing, and anticoagulation: preparation and characterization, Biomacromolecules, 6, 1041 (2005).
72. YI Chung, G Tae, SH Yuk, A facile method of prepare heparin- functionalized nanoparticles for controlled release of growth factors, Biomaterials, 27, 2621 (2006).
73. A Sahli, M Cansell, J Tapon-Bretaudiére, et al., The stability of heparin-coated liposomes in plasma and their effect on its coagulation, Colloids Surface B, 10, 205 (1998).
74. K Na, SW Kim, KS Park, et al., Heparin/poly(l-lysine) nanoparticle-coated polymeric microspheres for stem-cell therapy, J. Am. Chem. Soc., 129, 5788 (2007).
75. N Chinen, M Tanihara, M Nakagawa, et al., Action of microparticles of heparin and alginate crosslinked gel when used as injectable artificial matrices to stabilize basic fibroblast growth factor and induce angiogenesis by controlling its release, J. Biomed. Mater. Res., 67A, 61 (2003).
76. M Andersson, JE Loroth, Small particles of a heparin/chitosan complex prepared from a pharmaceutically acceptable microemulsion, Int. J. Pharm., 257, 305 (2003).
77. K Rajangam, HA Behanna, MJ Hui, et al., Heparin binding nanostructures to promote growth of blood vessels, Nano Lett., 6(9), 2086 (2006).
78. LD Thompson, MW Pantoliano, BA Springer, Energetic characterization of the basic fibroblast growth factor-heparin interaction: Identification of the heparin binding domain, Biochemistry, 33, 3831 (1994).
79. E Freire, OL Mayorga, M Straume, Isothermal titration calorimetry, Anal. Chem., 62, 950A (1990).
80. H Mach, DB Volkin, CJ Burke, et al., Nature of the interaction of heparin with acidic fibroblast growth factor, Biochemistry, 32, 5480 (1993).
81. H Gitay-Goren, S Soker, I Vladovsky, G Neufeld, The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules, J. Biol. Chem., 267, 6093 (1992).
82. F Bussolino, MF DiRenzo, M Ziche, et al., Hepatocyte growth. factor is a potent angiogenic factor which stimulates endothelial cell motility and growth, J. Cell. Biol., 119, 629 (1992).
83. D Naka, T Ishii, T Shimomura, et al., Heparin modulates the receptor-binding and mitogenic activity. of hepatocyte growth factor on hepatocytes, Exp. Cell. Res., 209, 317 (1993).
84. MA Palladino, RE Morris, HF Starnes, AD Levinson, The transforming growth factor-beta. A new family of immunoregulatory molecules, Ann. N. Y. Acad. Sci., 593, 181 (1990).
85. TA McCaffrey, DJ Falcone, B Du, Transforming growth factor-beta 1 is a heparin-binding protein: identification of putative heparin-binding regions and isolation of heparins with varying affinity for TGF-beta 1, J. Cell Physiol., 152, 430 (1992).
86. MJ Shon, SY Lee, TH Kim, et al., Effect of growth factors and dexamethasone on proliferation of bone marrow stromal cell, Tissue Eng. Regen, Med., 3(4), 457 (2006).
87. E Feyzi, F Lustig, G Fager, et al., Characterization of Heparin and Heparan Sulfate Domains Binding to the Long Splice Variant of Platelet-derived Growth Factor A Chain, J. Biol. Chem., 272, 5518 (1997).
88. R Langer, Drug delivery systems. XVI(9), MRS Bull, (1991).
89. AV Kabanova, EV Batrakova, VY Alakhov, Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery, J. Control. Release, 82, 189 (2002).
90. M Malmsten, Surfactants and polymers in drug delivery. New York: Elsevier, (2000).
91. SM Moghimi, AC Hunter, Poloxamers and poloxamines. in nanoparticle engineering and experimental medicine, Trends Biotechnol., 18, 412 (2000)
92. DM Salvay, LD Shea, Inductive tissue engineering with protein and DNA-releasing scaffolds, Mol. Biosyst., 2, 36 (2006).
93. TJ Cho, LC Gerstenfeld, TA Einhorn, Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing, J. Bone Miner. Res., 17, 513 (2002).
94. S Song, AJ Ewald, W Stallcup, et al., PDGFR beta + perivascular progenitor cells in tumors regulate pericyte differentiation and vascular survival, Nat. Cell. Biol., 7, 870 (2005).
95. G Terenghi, Peripheral nerve regeneration and neurotrophic factors, J. Anat., 194, 1 (1999).
96. Z Ahmed, RA Brown, C Ljungberg, et al., Nerve growth factor enhances peripheral nerve regeneration in non-human primates, Scand. J. Plast. Reconstr. Hand Surg., 33, 393 (1999).
97. A. Piotrowicz, MS Shoichet, Nerve guidance channels as drug delivery vehicles, Biomaterials, 27, 2018 (2006).